Expression of cyclin E and its relationship with the prognosis of patients with breast cancer
- 17 Downloads
- 2 Citations
Abstract
Objective: To investigate the expression of cyclin E in breast cancer tissues and its relationship with prognosis of the patients with breast cancer. Methods: The expression of cyclin E, HER-2/neu, nm23-H1 and actin was detected in 80 breast cancer tissues and 18 benign breast tumor tissues by immunohistochemical methods. The relationship between cyclin E and the remaining genes or the clinical data of the patients with breast cancer was analyzed. Results: The over expression rate of cyclin E in malignant tissues was obviously higher than that in benign tumor tissues (P<0.01). The over expression of cyclin E in later stage of disease was higher than that in early stage of disease (P<0.05). The expression of cyclin E in ER positive tissues was lower than that in ER negative tissues (P<0.05). The expression of cyclin E in PR positive tissues and PR negative tissues had no significant difference (P>0.05). The expression of cyclin E in HER-2/neu positive tissues was higher than that in HER-2/neu negative tissues (P<0.05). And the expression of cyclin E in ER, PR and HER-2/neu all positive tissues was much higher (P<0.01). There was no significant difference in the expression of cyclin E between nm23-H1 positive tissues and nm23-H1 negative tissues (P>0.05). The expression of cyclin E in actin positive and continuous distribution tissues was lower than that in actin negative or discontinuous distribution tissues (P<0.05). Conclusion: The expression of cyclin E has a strong correlation to the prognosis of the patients with breast cancer.
Key words
cyclin E breast tumor prognosisPreview
Unable to display preview. Download preview PDF.
References
- 1.Wu ZY, Zhen LL, Fan P. Mutation analysis in the BRCA1 gene in Chinese breast cancer Families. Chinese-German J Clin Oncol, 2003, 3: 153–155.Google Scholar
- 2.Sutherland RL, Musgrove EA. Cyclin E and prognosis in patients with breast cancer. N Engl J Med, 2002, 347: 1546–1547.PubMedCrossRefGoogle Scholar
- 3.Wu ZY, Zheng W. Expression of EGFR, C-erbB-2 protein in breast cancer and their relation with micrometastasis in bone marrow. Chinese-German J Clin Oncol, 2003, 2: 95–98.CrossRefGoogle Scholar
- 4.Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and incombination, correlate with survival in young breast cancer patients. Nat Med, 1997, 3: 152–154.CrossRefGoogle Scholar
- 5.Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. Hum Pathol, 2001, 32: 89–94.PubMedCrossRefGoogle Scholar
- 6.Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med, 2002, 347: 1566–1575.PubMedCrossRefGoogle Scholar
- 7.Han S, Park K, Bae BN, et al. Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. J Surg Oncol, 2003, 83: 241–247.PubMedCrossRefGoogle Scholar
- 8.Rudolph P, Kuhling H, Alm P, et al. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer, 2003, 105: 674–680.PubMedCrossRefGoogle Scholar
- 9.Span PN, Tjan-Heijnen VC, Manders P, et al. Cyclin E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene, 2003, 22: 4898–4904.PubMedCrossRefGoogle Scholar
- 10.Christov K, Ikui A, Shilkaitis A, et al. Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Breast Cancer Res Treat, 2003, 77: 253–264.PubMedCrossRefGoogle Scholar